|
Clinical significance of CTC enumeration on the Epic Sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients treated with AR signaling inhibitors (ARSi). |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
Consulting or Advisory Role - Epic Sciences; Epic Sciences (I) |
Travel, Accommodations, Expenses - Epic Sciences |
|
|
No Relationships to Disclose |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
Research Funding - Epic Sciences |
|
|
Stock and Other Ownership Interests - Biondvax; Gilead Sciences |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
Employment - Epic Sciences |
Leadership - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
Leadership - Asterias Biotherapeutics |
Stock and Other Ownership Interests - Asterias Biotherapeutics |
Honoraria - Research to Practice |
Consulting or Advisory Role - Ambry Genetics/Konica Minolta; Amgen; Bayer; ESSA; Janssen; Janssen Research & Development; Menarini Silicon Biosystems; Sanofi; WIRB-Copernicus Group |
Research Funding - Epic Sciences (Inst); Illumina (Inst); Innocrin Pharma (Inst); Janssen (Inst); Menarini Silicon Biosystems (Inst); Thermofisher Scientific Biomarkers (Inst) |
Travel, Accommodations, Expenses - Amgen; Asterias Biotherapeutics; Bayer; ESSA; Konica Minolta; Menarini Silicon Biosystems; Phosplatin Therapeutics; Prostate Cancer Foundation; Sanofi; WIRB-Copernicus Group |